Rosetta Genomics Signs Marketing Agreement With PACE Claims Services for miRview – Market Wire
Filed in Mesothelioma News on Jun.15, 2011
In a study published in The Journal of Molecular Diagnostics in September 2010, miRview® meso was shown to be a highly sensitive test for differentiating mesothelioma from carcinomas in the lung or pleura, with a sensitivity of 100% and a specificity of 94%.
View full post on mesothelioma – Bing News

Leave a Reply
You must be logged in to post a comment.